INmune Bio Inc. is a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer. Our drug candidates, INKmune and INB03, may be used alone or with conventional therapies to help eliminate disease in a wide variety of cancers. We believe they can also boost the effectiveness of other immunotherapies designed to enhance immune response to specific tumors. INKmune is a patented biologic that allows for the delivery of essential priming signals to patients’ resting NK cells. INB03 is a protein biologic that could inhibit proliferation and function of Myeloid-Derived Suppressor Cells (MDSC). By preventing the proliferation and function of MDSC, we believe patients will have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy.